Investigational Drug Information for IPI-549
✉ Email this page to a colleague
What is the development status for investigational drug IPI-549?
IPI-549 is an investigational drug.
There have been 5 clinical trials for IPI-549.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 17th 2019.
The most common disease conditions in clinical trials are Triple Negative Breast Neoplasms, Carcinoma, and Head and Neck Neoplasms. The leading clinical trial sponsors are Infinity Pharmaceuticals, Inc., Bristol-Myers Squibb, and Arcus Biosciences, Inc.
There are six US patents protecting this investigational drug and sixty-four international patents.
Summary for IPI-549
| US Patents | 6 |
| International Patents | 64 |
| US Patent Applications | 26 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2019-12-17) |
| Vendors | 42 |
Recent Clinical Trials for IPI-549
| Title | Sponsor | Phase |
|---|---|---|
| Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | The V Foundation for Cancer Research | Phase 2 |
| Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | Ezra Cohen | Phase 2 |
| Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) | Roche Pharma AG | Phase 2 |
Clinical Trial Summary for IPI-549
Top disease conditions for IPI-549
Top clinical trial sponsors for IPI-549
US Patents for IPI-549
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| IPI-549 | ⤷ Sign Up | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| IPI-549 | ⤷ Sign Up | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| IPI-549 | ⤷ Sign Up | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| IPI-549 | ⤷ Sign Up | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| IPI-549 | ⤷ Sign Up | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for IPI-549
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| IPI-549 | Australia | AU2016322552 | 2035-09-14 | ⤷ Sign Up |
| IPI-549 | Canada | CA2998469 | 2035-09-14 | ⤷ Sign Up |
| IPI-549 | China | CN108349985 | 2035-09-14 | ⤷ Sign Up |
| IPI-549 | China | CN114230571 | 2035-09-14 | ⤷ Sign Up |
| IPI-549 | European Patent Office | EP3350183 | 2035-09-14 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
